Behcet’s syndrome is common along the Old Silk Route that stretches from the Far East to the Mediterranean through which silk was traded. The reason for this distribution is not known. It is most common in Turkey where the number of cases varies between 80 to 370 per 100,000 people.
In Europe and United States, it is very rare and varies from 0.1 to 7.5 cases per 100,000 people.
Behcet’s syndrome belongs to a group of diseases called vasculitis. Most of the symptoms in this group are caused because small blood vessels are affected.
The symptoms continue over prolonged periods and recur even after treatment.
It causes mouth and genital ulcers, inflammation of the eye and skin. In addition, organs such as brain and spinal cord, digestive system, joints and large blood vessels are often affected.
Treatment includes drugs such as corticosteroids, indomethacin, sulfasalazine and mesalamine. Oral ulcers are treated with local corticosteroid gel.
Latest Publication and Research on Behcet's SyndromeTissue Expression of MLH1, PMS2, MSH2, and MSH6 Proteins and Prognostic Value of Microsatellite Instability in Wilms Tumor: Experience of 45 Cases. - Published by PubMed
Lack of efficacy of tocilizumab in mucocutaneous Behcet's syndrome: report of two cases. - Published by PubMed
Successful treatment by azacitidine therapy of intestinal Behçet's disease associated with myelodysplastic syndrome. - Published by PubMed
Branch retinal artery occlusion associated with posterior uveitis. - Published by PubMed
[Behcet's disease - ophthalmological and general aspects : Part 2: Therapy]. - Published by PubMed